Cardiac toxicity of immune checkpoint inhibitors: Cardio-oncology meets immunology

Circulation

Volumn 136, Issue 21, 2017, Pages 1989-1992

  Varricchi, Gilda ^a   Galdiero, Maria Rosaria ^a   Tocchetti, Carlo G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiotoxicity; Immune system; Myocarditis; Neoplasms

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNE MYOCARDITIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARDIOLOGIST; CARDIOTOXICITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CD8+ T LYMPHOCYTE; DEATH; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HEART BLOCK; HISTOPATHOLOGY; HYPERTENSION; IMMUNOLOGIST; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MELANOMA; MONOTHERAPY; MYOCARDITIS; ONCOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; CARDIOLOGY; CHEMICALLY INDUCED; HEART DISEASE; HUMAN; IMMUNOLOGY; INTERDISCIPLINARY COMMUNICATION; NEOPLASM; ONCOLOGY; PATHOLOGY; PATIENT CARE; RISK FACTOR;

ALLERGY AND IMMUNOLOGY; ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARDIOLOGY; CARDIOTOXICITY; HEART DISEASES; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT CARE TEAM; RISK FACTORS;

EID: 85042198550     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.029626     Document Type: Review

References (5)

1. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19:21. doi:10.1007/s11886-017-0835-0.
2. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384-3391. doi:10.1172/JCI80011.
3. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-1755. doi:10.1056/NEJMoa1609214.
4. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319- 322. doi:10.1126/science.291.5502.319.
5. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368-376. doi:10.1093/annonc/mdw443.